Abstract
Critical limb-threatening ischemia (CLTI) is a health care priority; since 2010, there has been a 50% increase of non-traumatic major amputations. We have previously shown that autologous bone marrow cell therapy is not effective in preventing amputations on patients with poor options for revascularization. Allogeneic mesenchymal stromal cells (MSCs) from young healthy donors may have greater therapeutic potential, particularly in diabetic populations. Here, we describe the effects of intramuscular injection of vertebral body adherent (vBA)-MSCs in restoring limb perfusion, muscle regeneration and limb function in two diabetic CLTI mouse models.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
